Psychiatric Genomics and the University of Louisville Enter Into Collaborative Research Project, License Agreement


GAITHERSBURG, Md., April 23 /PRNewswire/ -- Psychiatric Genomics, Inc. ("PsyGenomics") and the University of Louisville ("UofL") are pleased to announce the recent signing of two agreements. Under the terms of the first, PsyGenomics will support a research project at UofL to further the ground- breaking work of Drs. Fred J. Roisen, Kathleen Klueber and Chengliang Lu in UofL's Department of Anatomical Sciences and Neurobiology and Dr. Welby Winstead in UofL's Department of Surgery on human olfactory neuroepithelial cells.

Under the terms of the second agreement, PsyGenomics will receive an exclusive license to use several of the cell lines in its gene and drug discovery programs. Gene discovery at PsyGenomics is done using differential expression analysis to identify the genetic signatures of mental illness. The company's drug discovery programs use a newly invented Multi-Parameter High Throughput Screening(SM) system to monitor the effects of novel compounds on the activity of multiple genes simultaneously.

Dr. Roisen's team is looking into the therapeutic value to the central nervous system of cells grown from adult olfactory tissue. The long-term goal of the research is to allow spinal cord injury victims or patients with neurodegenerative diseases to provide their own donor tissue.

Dr. Richard E. Chipkin, Chief Executive Officer of Psychiatric Genomics, Inc. commented:

"Psychiatric Genomics is pleased to be working with Dr. Roisen's lab at

the University of Louisville. Their research on cultured human olfactory

neuroepithelial cells is ground-breaking and represents a new source of

cells capable of differentiating into fully mature human neurons."

Dr. Roisen said:

"I am pleased that Psychiatric Genomics has recognized the value of our

work on neuroepithelial cells and are willing to invest in further

refinements of our technology. I look forward to a long and fruitful

collaboration in this new field."

Notes:

1. Psychiatric Genomics, Inc. is dedicated to harnessing the power of

genomics to discover novel therapeutics for psychiatric disorders.

Many psychiatric disorders such as schizophrenia, depression, and

bipolar disorders can be attributed to genetic factors. By

understanding the genes and genetic pathways associated with various

psychiatric diseases, Psychiatric Genomics discovers and develops new

drugs for treating these disorders.

2. University of Louisville, More than 20,000 undergraduates, graduate

and professional students attend the University of Louisville

(http://www.louisville.edu ), a metropolitan research university

located in the heart of Kentucky's largest city. The university is

known as a pioneer in health-sciences research, particularly in the

areas of transplantation, cardiology, neurosciences, pediatrics, and

genetics and molecular medicine.

CONTACT:

For Psychiatric Genomics, Inc.

Ms. Meg Breitenbach

Psychiatric Genomics, Inc.

301-556-1300

mbreitenbach@psygenomics.com

http://www.psygenomics.com

[This message was edited by seneca on Apr 23, 2002 at 09:30 AM.]